A Nashville infusion therapy company has quietly opened a flurry of D.C.-area locations within the past few months — and intends to bring more to the market this year.
Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...
UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...
NHS patients with sickle cell disease will be able to benefit from a groundbreaking gene-editing treatment that offers the prospect of a cure for the condition. The one-off gene therapy, known as ...
Systems (NASDAQ: KRMD), a medical technology firm with a market capitalization of $194 million, announced a partnership with a global pharmaceutical manufacturer to conduct a Phase III clinical trial.